The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).
 
Ritujith Jayakrishnan
No Relationships to Disclose
 
Amin Nassar
No Relationships to Disclose
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Bayer; Blueprint Medicines; Bristol Myers Squibb; C4 Therapeutics; CLaiM Therapeutics; Daiichi Sankyo/Astra Zeneca; Elevation Oncology; Ellipses Pharma; Genentech; Merus; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Turning Point Therapeutics; Yuhan
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Merus; Pfizer
 
Steven H. Lin
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - SEEK Diagnostics
Honoraria - AstraZeneca/MedImmune; BeyondSpring Pharmaceuticals
Research Funding - BeyondSpring Pharmaceuticals; Nektar; STCube Pharmaceuticals Inc.
 
Purnima Shakya
No Relationships to Disclose
 
Thomas J. Dilling
No Relationships to Disclose
 
Jair Bar
Stock and Other Ownership Interests - Causalis
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Immunai (Inst); MSD (Inst); Novartis (Inst); Oncohost (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Christian Grohe
No Relationships to Disclose
 
Shruti Gupta
No Relationships to Disclose
 
Bailey Gleason Fitzgerald
No Relationships to Disclose
 
Elio Adib
Employment - Amgen (I)
 
Kamya Sankar
No Relationships to Disclose
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; HMP Education; Medical Educator Consortium; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; D2G Oncology; Exelixis; Genentech/Roche; Gilead Sciences; Iovance Biotherapeutics; Janssen Oncology; Lilly; Mirati Therapeutics; Natera; Novartis; Novocure; Regeneron; Sanofi/Regeneron; Summit Therapeutics; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Helena Alexandra Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Taiho Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma
 
Ryan Whitaker
No Relationships to Disclose
 
Ana I. Velazquez Manana
Stock and Other Ownership Interests - Corbus Pharmaceuticals
Honoraria - Curio Science; Guidepoint Pharmacy; MDOutlook; MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Merus NV; Novocure; Regeneron
Travel, Accommodations, Expenses - DAVA Oncology
Other Relationship - Pfizer
 
Abdul Rafeh Naqash
Honoraria - NGM Biopharmaceuticals
Consulting or Advisory Role - foundation me
Travel, Accommodations, Expenses - American Society for Radiation Oncology; ASCO; Binacea; Foundation Medicine; Jazz Pharmaceuticals (Inst); Society for Immunotherapy of Cancer
 
Sarah B. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca/MedImmune; Daiichi Sankyo; Genzyme; Janssen; Merck; Regeneron; Summit Therapeutics
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; ORIC Pharmaceuticals (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
So Yeon Kim
Consulting or Advisory Role - Amgen
Research Funding - Boehringer Ingelheim (Inst); Genmab (Inst); Loxo/Lilly (Inst)